Pernix Therapeutics Announces Restructuring and Integration of the Pernix and Hawthorn Sales Forces
News Jan 25, 2013
The sales force will remain focused on Pediatrics, Primary Care and Gastroenterology.
The Company today also announced that David Becker will resign his position as Chief Financial Officer, due to personal reasons, effective March 31, 2013. The Company has started a search to identify a new Chief Financial Officer. Upon naming a successor, Mr. Becker will serve the Company as a consultant in several areas, including manufacturing, over-the-counter products, and business development.
Cooper Collins, President and CEO of Pernix, said, “We closed the acquisition of Cypress and Hawthorn at the end of December, and we are rapidly making progress in the implementation of our integration plans. In addition, we appreciate the service that David has provided the Company, which included building our OTC product group and completing several key business development transactions that have broadened the scope of our business and expanded our portfolio of branded and generic products.”
SYGNIS AG Signs Supply Agreement with US Biological for the Lightning-Link Antibody Labelling TechnologyNews
SYGNIS AG, the Group which includes Expedeon Holdings, Innova Biosciences, and C.B.S. Scientific Company, announced it has signed a supply agreement with US Biological, Salem, MA, USA, for its Innova Lightning-Link® technology.READ MORE
Chemists Design More Efficient Microreactor Using 3D PrintingNews
Researchers developed an electrochemical microreactor using additive manufacturing technology (commonly known as 3D printing). The newly developed microreactor was tested on synthesis of isoindolinones, which are found in many natural products, pharmaceuticals, and biologically active molecules.READ MORE